[1]Bahadoer RR,Dijkstra EA,van Etten B,et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy,TME,and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised,open-label,phase 3 trial [J]. Lancet Oncol,2021, 22(1):29-42.[2]Conroy T,Bosset JF,Etienne PL,et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre,randomised,open-label,phase 3 trial [J]. Lancet Oncol, 2021, 22(5):702-715.
[3]国家卫生健康委员会医政司, 中华医学会肿瘤学分会. 国家卫生健康委员会中国结直肠癌诊疗规范(2023版)[J]. 中华胃肠外科杂志, 2023, 26(6): 505-528.
[4]Scott AJ, Kennedy EB, Berlin J, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024 Oct;42(28):3355-3375.
[5]Ominelli J,Valadão M,Araujo R,et al. The evolving field of neoadjuvant therapy in locally-advanced rectal cancer: evidence and prospects [J]. Clin Colorectal Cancer, 2021, 20(4):288-298.
[6]Kim SY, Joo J, Kim TW, et al. A randomized phase 2 trial of consolidation chemotherapy after preoperative chemoradiation therapy versus chemoradiation therapy alone for locally advanced rectal cancer: KCSG CO 14-03 [J]. Int J Radiat Oncol Biol Phys,2018,101(4):889-899.
[7]王晔,楼征,季力强,等. 局部进展期直肠癌全程新辅助治疗临床应用进展[J]. 中国实用外科杂志,2023,43(4):461-464.
[8]Fokas E, Schlenska-Lange A, Polat B, et al; German Rectal Cancer Study Group. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. JAMA Oncol. 2022 Jan 1;8(1):e215445.
[9]Xia F, Wang Y, Wang H, et al. Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH). J Clin Oncol. 2024 Oct;42(28):3308-3318.
[10]冯波, 马韬. 局部进展期直肠癌全程新辅助治疗的发展与挑战[J]. 中国实用外科杂志,2024,44(7):744-751.